PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Levomenthol→

Levomenthol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2216-51-5
Molecular formula
C10H20O
Molecular weight
156.2652 g/mol
Drug class
Topical counterirritant and local cooling agentTRPM8 agonist
Mechanism of action
Activates cold-sensitive transient receptor potential melastatin-8 (TRPM8) channels in cutaneous sensory nerves, producing a cooling sensation. Counter-irritant and sensory-modulating effects can reduce perception of local pain or discomfort.
Indications / reported uses
  • Topical relief of headache with authorised cutaneous formulations.
  • Symptomatic relief of nasal congestion and common-cold symptoms with authorised nasal preparations.
  • Topical relief of minor muscle and joint pain in appropriate combination products.

Sources: https://www.medicines.org.uk/emc/product/305/smpc · https://www.medicines.org.uk/emc/product/297/smpc · https://pubmed.ncbi.nlm.nih.gov/29524352/ · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Levomenthol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levomenthol Permitted Daily Exposure (PDE) report (the Levomenthol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levomenthol Occupational Exposure Limit (OEL) report (the Levomenthol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.